LG Chem has strengthened the credibility of its short stature treatment, Eutropin, by releasing long-term safety and efficacy data.
On June 11, LG Chem announced the interim analysis results of its long-term observational study on Eutropin during the 21st LG Growth Study (LGS) Symposium, aimed at pediatric endocrinologists. The company also introduced its new product, Eutropin EcoPen 48 (referred to as EcoPen).
The LGS study, which began in 2012 and will continue until 2035, is a long-term research project involving 10,000 children in South Korea to gather data on the long-term administration of the growth hormone Eutropin. As of the end of last year, approximately 8,000 patients had been enrolled.
During the symposium, Professors Lee Young-a and Kim Ja-hye from Seoul National University Hospital and Asan Medical Center, respectively, presented findings on the long-term safety and efficacy analysis over 13 years, as well as treatment approaches for growth hormone deficiency and idiopathic short stature.
Professor Lee reported that the interim analysis of safety data from 2012 to 2025 showed a low incidence of serious adverse drug reactions (SADRs) at 0.2%, with overall safety indicators remaining favorable.
In terms of efficacy, the standard deviation of height improved over four years of treatment, with the growth hormone deficiency group showing a change from -2.3 to -0.8, and the idiopathic short stature group from -2.3 to -1.0. Notably, a higher improvement trend was observed in patients who began treatment before puberty.
Professor Kim highlighted stable maintenance of endocrine and metabolic indicators, such as thyroid function and blood glucose, based on a seven-year long-term exposure analysis of growth hormone treatment.
Son Ji-woong, head of LG Chem's Life Sciences Division, expressed hope that the LGS study would serve as a guiding compass for short stature treatment in South Korea, contributing to the dreams of children.
Additionally, LG Chem unveiled a new Eutropin product equipped with a pen injector in April. The EcoPen is designed to be used multiple times by combining a dedicated cartridge, Eutropin Cartridge 48 IU, with the pen device, differing from the previous all-in-one cartridge product, Eutropin SPEN. The injection button is fixed at a length of 3mm, ensuring consistent low injection pressure.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.